Price T Rowe Associates Inc. MD Buys 381,145 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Price T Rowe Associates Inc. MD boosted its stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 2,968.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 393,984 shares of the company's stock after buying an additional 381,145 shares during the period. Price T Rowe Associates Inc. MD owned approximately 1.68% of UroGen Pharma worth $4,197,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in URGN. KLP Kapitalforvaltning AS bought a new position in shares of UroGen Pharma during the fourth quarter valued at $59,000. Oppenheimer & Co. Inc. purchased a new stake in UroGen Pharma during the 4th quarter valued at about $126,000. Legal & General Group Plc increased its stake in UroGen Pharma by 24.6% during the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock valued at $211,000 after purchasing an additional 3,920 shares in the last quarter. SG Americas Securities LLC raised its holdings in UroGen Pharma by 44.1% in the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock worth $216,000 after buying an additional 6,207 shares during the last quarter. Finally, MetLife Investment Management LLC raised its holdings in UroGen Pharma by 13.6% in the fourth quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock worth $242,000 after buying an additional 2,727 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.

UroGen Pharma Stock Performance

UroGen Pharma stock traded down $0.32 during trading on Friday, reaching $10.35. The company had a trading volume of 502,562 shares, compared to its average volume of 541,598. The firm's 50-day simple moving average is $10.64 and its 200 day simple moving average is $10.99. UroGen Pharma Ltd. has a 52 week low of $8.94 and a 52 week high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The firm has a market capitalization of $477.21 million, a price-to-earnings ratio of -3.29 and a beta of 0.66.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The firm had revenue of $24.57 million during the quarter, compared to analysts' expectations of $25.25 million. Sell-side analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on URGN shares. Scotiabank began coverage on UroGen Pharma in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price objective on the stock. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $55.00 price target on shares of UroGen Pharma in a report on Monday, April 28th. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Thursday. Finally, The Goldman Sachs Group dropped their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating on the stock in a report on Thursday, April 17th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $32.86.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.